- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 2770300-35-9] KR-39038
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-143248 |
| Brand: | MCE |
| CAS: | 2770300-35-9 |
Overview
| MDL | - |
|---|---|
| Molecular Weight | 475.00 |
| Molecular Formula | C24H32ClFN6O |
| SMILES | O=C1N=C(C2=C(Cl)C=CC=C2)NC3=CC(NCCCNCCCCNCCCN)=C(C=C13)F |
Summary
KR-39038 is an orally active and potent GRK5 (G protein-coupled receptor kinase 5) inhibitor, with an IC 50 of 0.02 μM. KR-39038 significantly inhibits angiotensin II-induced cellular hypertrophy through suppression of HDAC5 pathway in neonatal cardiomyocytes. KR-39038 shows profound anti-hypertrophic effects and improved cardiac function. KR-39038 can be used for heart failure research [1] .
IC50 & Target
|
HDAC5
|
In Vitro
KR-39038 (0-1.0 μM, 24 h) significantly inhibits angiotensin II-induced cellular hypertrophy and HDAC5 phosphorylation in neonatal cardiomyocytes [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Western Blot Analysis [1]
| Cell Line: | Primary neonatal cardiomyocytes (isolated from S.D. rats (1-2 days old) using primary myocardial cell isolation kit) |
| Concentration: | 0 μM, 0.03 μM, 0.1 μM, 0.3 μM, 1.0 μM |
| Incubation Time: | 24 h |
| Result: | Significantly inhibited angiotensin II-induced cellular hypertrophy at a concentration of 0.1 µM and higher concentrations. Decreased angiotensin II-induced HDAC5 phosphorylation at 0.3 µM and higher concentrations. |
In Vivo
KR-39038 (0-30 mg/kg, Orally, once daily for 14 days) effectively attenuates both cardiac hypertrophy and dysfunction in experimental heart failure
[1]
.
Pharmacokinetic Parameters of KR-39038 in Sprague-Dawley rats
[1]
.
| Parameters | IV (5 mg/kg) | PO (300 mg/kg) |
| C max (µg/mL) | NA | 5.2 ± 2.8 |
| T max (h) | NA | 0.7 ± 0.2 |
| t 1/2 (h) | 0.7 ± 0.04 | 2.3 ± 2.9 |
| AUC 0-∞ (µg*h/mL) | 3.4 ± 1.0 | 8.9 ± 5.0 |
| CL (L/h/kg) | 1.6 ± 0.5 | NA |
| Vss (L/kg) | 1.2 ± 0.2 | NA |
| F (%) | 4.3 ± 2.4 |
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | C57BL/6 mice (male, 20-24 g, transverse aortic constriction) [1] |
| Dosage: | 30 mg/kg |
| Administration: | Orally, once a day for 2 weeks, starting from 24 h after the operation |
| Result: | Showed a 43% reduction in the left ventricular weight, and significantly attenuated the development of cardiac hypertrophy. |
| Animal Model: | Sprague-Dawley (S.D.) rats (male, 380-420 g, coronary artery ligation) [1] |
| Dosage: | 10 mg/kg, 30 mg/kg |
| Administration: | Orally, once a day for 12 weeks, starting from 24 h after surgery |
| Result: | Showed significant preservation of cardiac function and attenuation of myocardial remodeling in a rat model of chronic heart failure following coronary artery ligation. |
| Animal Model: | Sprague-Dawley (S.D.) rats [1] |
| Dosage: | 5 mg/kg (IV), 300 mg/kg (Orally) |
| Administration: | IV or Orally, single (Pharmacokinetic Analysis) |
| Result: | The AUC ∞ values after intravenous injection with 10 mg/kg and oral administration of 300 mg/kg of KR-39038 were 3.4 ± 1.0 and 8.9 ± 5.0 µg·h/mL, respectively, resulting in 4.3% bioavailability. |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, stored under nitrogen, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)
Solvent & Solubility
DMSO : 115 mg/mL ( 242.11 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.1053 mL | 10.5263 mL | 21.0526 mL |
| 5 mM | 0.4211 mL | 2.1053 mL | 4.2105 mL |
| 10 mM | 0.2105 mL | 1.0526 mL | 2.1053 mL |
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.